Isabella C. Glitza Oliva, MD, PhD, MS, discusses the potential utility of pembrolizumab in combination with selinexor in advanced melanoma.
Isabella C. Glitza Oliva, MD, PhD, MS, assistant professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential utility of pembrolizumab (Keytruda) in combination with selinexor (Xpovio) in advanced melanoma.
During the 2020 ESMO Virtual Congress, initial findings from a phase 1b study (NCT02419495) showed significant clinical activity in patients with metastatic melanoma.
Notably, no new safety signals were observed with the combination, which allowed the study to meet its primary objective of safety and tolerability, Glitza Olivia explains.
These findings warrant additional investigation with the combination. Moreover, the trial is evaluating selinexor in combination with various standard chemotherapy or immunotherapy regimens across multiple advanced malignancies.
Additionally, investigators are evaluating the triplet combination of ipilimumab (Yervoy), nivolumab (Opdivo), and selinexor in patients with melanoma and advanced solid malignancies, Glitza Olivia concludes.